---
categories: 
- Database
- Release
date: 2024-11-07
title: Database release
---
This release contains 997 approved relationships.

Added entries:
- (FDA) [_BCR_::_ABL1_ and sensitivity to asciminib](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-asciminib-newly-diagnosed-chronic-myeloid-leukemia) for patients with chronic myeloid leukemia in chronic phase.
- (FDA) _BCR_::_ABL1_ and _ABL1_ p.T315I and sensitivity to asciminib for patients with chronic myeloid leukemia in chronic phase.
- (FDA) [_PIK3CA_ variants and sensitivity to inavolisib for patients with HR+, HER2-negative, locally advanced or metastatic breast cancer](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive).

Revised entries:
- (FDA) _BCR_::_ABL1_ and sensitivity to asciminib for patients with previously treated chronic myeloid leukemia in chronic phase was generalized to be for previously treatmented patients, instead of specifically for previously treated with two or more TKIs.